Modelling Cost-Effectiveness of Biologic Treatments Based on Disease Activity Scores for the Management of Rheumatoid Arthritis in Spain

Table 3

Summary of effectiveness probabilities (percentage of patients achieving LDAS).

Biological agent		%LDAS	Source
Abatacept after IR to anti-TNF therapy	Induction—Month 12; Maintenance; Month 18; Month 24	18.3%; 24.2%; 28%	ATTAIN + LTE study (Genovese 2007); ATTAIN + LTE study (Genovese 2007); ATTAIN + LTE study (Genovese 2007)
Abatacept after IR to 2 anti-TNF agents	Induction—Month 18; Maintenance—Month 24	24.5%; 21.5%	ATTAIN reanalysis after IR to 2 anti-TNF agents (EULAR 2008); ATTAIN reanalysis after IR to 2 anti-TNF agents
Anti-TNF agents	Induction—Month 18; Maintenance—Month 24	11%; 21.5%	REACT trial (Bombardieri 2007); ATTAIN reanalysis after IR to 2 anti-TNF agents
Rituximab after IR to anti-TNF therapy	Induction—Month 12; Maintenance; Month 18; Month 24	13%; 25%; 29%	REFLEX + LTE study (Keystone 2007); REFLEX + LTE study (Keystone 2007); Keystone (EULAR 2007)
DMARDS	Month 24	5%	Clinical experts opinion

IR: insufficient response; LDAS: low disease activity State (DAS28 ≤ 3.2).